1. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
   Li Liu et al, 2021, Frontiers in Oncology CrossRef
2. Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape
   Anurag Mehta et al, 2020, Applied Cancer Research CrossRef
3. Mutational Landscape and In-Silico Analysis of TP53, PIK3CA, and PTEN in Patients with Breast Cancer from Khyber Pakhtunkhwa
   Hilal Ahmad et al, 2023, ACS Omega CrossRef
4. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland
   Alexandra Grosse et al, 2019, Diagnostic Pathology CrossRef
5. Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review
   Jasmina Obradovic et al, 2021, Molecular Biology Reports CrossRef
6. Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer
   Mansi Gupta et al, 2023, Diseases and Research CrossRef
7. Quantitative structure–activity relationships analysis, homology modeling, docking and molecular dynamics studies of triterpenoid saponins as Kirsten rat sarcoma inhibitors
   Mourad Stitou et al, 2021, Journal of Biomolecular Structure and Dynamics CrossRef